Lung Cancer Clinical Trial
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
Summary
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway. The study will assess prospectively the efficacy of erlotinib as a single agent or intercalated with chemotherapy in highly selected patients with EGFR overexpression and/or EGFR amplification.
Eligibility Criteria
Inclusion Criteria:
Age >= 18
Histologically or cytologically documented non-small cell lung cancer (NSCLC)
Eastern Cooperative Oncology Group (ECOG)performance status (PS)0, 1, 2
Radiologically measurable or evaluable disease No prior chemotherapy
1 or 2 epithelial growth factor receptor (EGFR) pathway markers positive at screening
Tumor tissue block or fine needle aspirate
Exclusion Criteria:
Any concurrent anticancer therapy or radiation
Other active malignancy
Uncontrolled brain metastases
GI abnormalities
Severe abnormalities of the cornea
Significant cardiac disease
Active infection
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 42 Locations for this study
Alhambra California, 91801, United States
Bakersfield California, 93309, United States
Concord California, 94520, United States
Fullerton California, 92835, United States
Long Beach California, 90813, United States
Los Angeles California, 90095, United States
Northridge California, 91325, United States
Oxnard California, 93030, United States
Pomona California, 91767, United States
Redondo Beach California, 90277, United States
Santa Barbara California, 93105, United States
Santa Barbara California, 93105, United States
Aurora Colorado, 80045, United States
Denver Colorado, 80218, United States
Norwich Connecticut, 06360, United States
Orlando Florida, 32806, United States
Tampa Florida, 33614, United States
Lawrenceville Georgia, 30045, United States
Macon Georgia, 31201, United States
Chicago Illinois, 60612, United States
Chicago Illinois, 60637, United States
Louisville Kentucky, 40202, United States
Detroit Michigan, 48201, United States
Minneapolis Minnesota, 55455, United States
Billings Montana, 59101, United States
Omaha Nebraska, 68124, United States
Henderson Nevada, 89052, United States
Mount Holly New Jersey, 08060, United States
Portland Oregon, 97213, United States
Philadelphia Pennsylvania, 19111, United States
Pottsville Pennsylvania, 17901, United States
Memphis Tennessee, 38104, United States
Memphis Tennessee, 38120, United States
Memphis Tennessee, 38138, United States
Houston Texas, 77030, United States
Burlington Vermont, 05401, United States
Chesapeake Virginia, 23320, United States
Seattle Washington, 98109, United States
Birmingham , B9 5S, United Kingdom
Cambridge , CB2 2, United Kingdom
Cambridge , PE3 6, United Kingdom
Glasgow , G11 6, United Kingdom
Middlesex , HA6 2, United Kingdom
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.